Repaired tetralogy of Fallot across adulthood: from right ventricular remodelling to targeted intervention Authors: Krzysztof Cienkowski, Maciej Moll, Alicja Cienkowska, Karolina Kupczynska, Maciej Banach, Agata Bielecka-Dabrowa Published: 2026 ABSTRACT AbstractAdults with repaired tetralogy of Fallot (rTOF) constitute a rapidly growing adult congenital heart disease population with excellent early survival but substantial late morbidity. Chronic pulmonary regurgitation and/or residual right ventricular outflow tract obstruction drive progressive right ventricular dilatation, dysfunction, dyssynchrony, and myocardial fibrosis, predisposing to heart failure and ventricular arrhythmias. This review summarizes contemporary concepts in the surveillance and management of adults with rTOF, focusing on multimodality imaging, pulmonary valve replacement (PVR), arrhythmia risk stratification, aortopathy, and emerging pharmacological strategies. Echocardiography remains the first-line modality for assessing residual lesions and aortic dimensions, while cardiac magnetic resonance is central for quantifying right ventricular volumes, regurgitant fraction, and fibrosis; computed tomography complements anatomical evaluation when magnetic resonance imaging is not feasible. PVR, increasingly performed using transcatheter techniques, is a cornerstone intervention, with guideline-based decisions integrating symptoms, right ventricular volumes, functional testing, and ventricular function. Arrhythmia management combines risk stratification, catheter ablation, implantable cardioverter-defibrillators in selected patients, and individualized medical and pacing therapies. Aortic root dilatation is common, but dissection is rare; surveillance and surgery are guided by diameter thresholds and growth rate. Evidence for routine renin–angiotensin–aldosterone inhibition to improve right ventricular function remains limited, although selected agents and exercise-based interventions are under investigation. Infective endocarditis risk differs by pulmonary valve replacement modality and valve type, being generally higher after transcatheter than surgical replacement, and warrants individualized antiplatelet therapy and vigilant surveillance after implantation. Lifelong multidisciplinary follow-up in specialized adult congenital heart disease centers is essential to optimize reintervention timing and reduce arrhythmic and aortic complications in adults with rTOF. Graphical abstract summarises the overall pathophysiology and long-term management of repaired tetralogy of Fallot.Graphical Abstract Keywords: Tetralogy of Fallot, Adult congenital heart disease, Pulmonary valve replacement, Pulmonary regurgitation, Right ventricular dysfunction Introduction Tetralogy of Fallot (TOF) is a complex congenital heart defect characterized by four anatomical features: ventricular septal defect (VSD), overriding aorta, right ventricular outflow tract obstruction (RVOTO), and right ventricular hypertrophy (RVH). Most cases are non-syndromic, while about 20% are associated with genetic syndromes such as 22q11 deletion, Down, Alagille, Noonan, or Williams syndromes [1]. Although surgical repair has markedly improved survival, patients with repaired TOF (rTOF) continue to have higher mortality than those with simpler congenital heart defects [2]. The most common long-term complication is pulmonary regurgitation (PR), particularly after transannular patch repair, leading to progressive right ventricular (RV) dilation, dysfunction, and heart failure [3]. Residual RVOTO further increases RV pressure and limits exercise capacity [4], while residual VSD, aortic root dilation, and chronic volume overload may contribute to biventricular dysfunction and heart failure [5–8]. Atrial and ventricular arrhythmias remain important causes of morbidity and sudden cardiac death [2]. Both surgical and transcatheter pulmonary valve replacement (TPVI) are associated with a risk of infective endocarditis, particularly in patients with prosthetic valves [9]. While several reviews have addressed individual aspects of long-term management in repaired tetralogy of Fallot, this review provides an integrated, up-to-date synthesis spanning pulmonary valve replacement (including the newly published 2026 STS/WSPCHS/ECHSA clinical practice guidelines [10]), comparative endocarditis risk across both established and emerging transcatheter valve platforms, arrhythmia and aortopathy management, and evolving pharmacological strategies targeting right ventricular dysfunction — offering clinicians a single, current reference point across the full spectrum of late complications in this population. Figure 1 summarises the major late complications and contemporary management strategies in adults with repaired tetralogy of Fallot. Major late complications and management strategies in adults with repaired tetralogy of Fallot. Image(s) provided by Servier Medical Art (https://smart.servier.com), licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) Methodology This narrative review was based on a comprehensive search of the PubMed/MEDLINE and Cochrane Library databases for articles published up to [June 2026], with no lower date limit to include seminal studies on the natural history and surgical management of tetralogy of Fallot. The search strategy combined the terms “tetralogy of Fallot”, “repaired tetralogy of Fallot”, “Adult congenital heart disease”, “Pulmonary regurgitation”, “Right ventricular remodeling”, “Pulmonary valve replacement”, “Aortopathy”, and “Arrhythmia”, using Boolean operators and Medical Subject Headings (MeSH) where applicable. We manually screened the reference lists of retrieved articles and relevant systematic reviews and guidelines to identify additional eligible studies. We considered original research articles, meta-analyses, systematic reviews, and current clinical guidelines published in English, prioritising studies of adult populations with repaired tetralogy of Fallot. We excluded case reports, non-peer-reviewed sources, and studies limited to pediatric cohorts without long-term follow-up data unless they provided mechanistic insight relevant to disease pathophysiology. Titles and abstracts were first screened for relevance, followed by full-text assessment of potentially eligible articles; the final selection was based on methodological quality and clinical relevance to the topics addressed in this review. Diagnosis and multimodality imaging Diagnosis in adults after TOF repair requires clinical assessment combined with multimodal imaging. Clinical examination and electrocardiography (ECG) may identify residual lesions, with QRS prolongation reflecting right ventricular (RV) dilation [2]. Echocardiography is the first-line imaging modality for assessing residual defects, ventricular size and function, tricuspid regurgitation, and aortic root dimensions, while strain analysis provides additional information on electromechanical dyssynchrony [11, 12]. Cardiac magnetic resonance (CMR) is the gold standard for evaluating RV volumes, function, pulmonary regurgitation (PR), and myocardial fibrosis, whereas cardiac computed tomography (CCT) is useful when CMR is contraindicated and for detailed anatomical assessment [2]. Cardiopulmonary exercise testing (CPET), Holter monitoring, electrophysiological studies, and, in selected cases, cardiac catheterization complement imaging by assessing exercise capacity, arrhythmia risk, and pre-interventional anatomy [2, 13, 14]. Despite improved survival after repair, adults with TOF require lifelong multidisciplinary follow-up focused on the early detection and management of PR, arrhythmias, aortic complications, and progressive ventricular dysfunction [2]. Long-term outcomes Tetralogy of Fallot can be surgically corrected with low procedural mortality and excellent long-term survival. Over recent decades, the use of transventricular approaches and palliative shunts has declined markedly, reflecting advances in surgical techniques and perioperative management. Depending on individual anatomy and clinical condition, a complete single-stage repair can be safely performed as early as three months of age. Despite these favorable outcomes, the need for reinterventions throughout life remains substantial, as most patients will require one or more additional procedures, highlighting the importance of lifelong follow-up and careful management of associated structural or genetic abnormalities, which are frequently encountered in this population [15]. A meta-analysis of over 21,000 patients with a total follow-up of 147,000 patient-years demonstrated a mean age at complete repair of 3.7 ± 5.6 years, which decreased to 0.5 ± 2.5 years when studies focusing exclusively on adult repairs were excluded, reflecting a clear shift toward early primary correction [15]. In adults undergoing elective repair, surgery can be performed safely, resulting in significant functional improvement; however, early mortality remains higher (7.55%) than in pediatric cohorts, with a late mortality rate of 0.95% per year. Across the overall population, early mortality was 2.84%, and late mortality was 0.42% per year, with cardiac-related mortality estimated at 0.26% per year. Valve-related mortality was 0.20% per year, while non–valve-related mortality was 0.17% per year, highlighting the ongoing clinical relevance of both pulmonary valve dysfunction and other cardiac causes in long-term outcomes. Among TOF patients, the most common genetic abnormalities were Down syndrome (4.6%) and 22q11.2 deletion (4%) [15]. Long-term outcomes in adults are strongly influenced by the surgical approach used for right ventricular outflow tract (RVOT) and pulmonary valve management. The most frequently applied techniques included a transventricular approach (39%), transannular patch (TAP, 49%), and prior palliative shunts (16%). While TAP use has remained relatively stable over the past decades, emphasis has increasingly shifted to pulmonary valve–sparing strategies to minimize chronic pulmonary regurgitation (PR) [15]. Since the early 2000 s, growing awareness of the detrimental effects of PR has led to more selective TAP application, particularly in younger patients, in whom TAP has been associated with higher rates of late adverse events [16]. Importantly, the likelihood of TAP use depends more on the severity of RVOT obstruction and patient symptomatology than on age alone [17]. When TAP is required, it effectively reduces the risk of RVOT restenosis and does not adversely affect long-term survival or reintervention rates. However, it carries a risk of significant postoperative PR [18]. To further reduce PR, valve-sparing approaches have been increasingly employed. Studies have shown that a transatrial–transpulmonary approach with limited right ventricular incision and restrictive annular enlargement allows safe repair in patients with a pulmonary annulus z-score above –4 [19, 20], while avoiding TAP entirely in annuli with z-scores above –2 [20], resulting in low reintervention rates and no significant residual RVOT obstruction. Similarly, limiting the transannular incision to less than 5 mm into the infundibulum has been associated with 96% freedom from reoperation at 7 years [21]. Comparative analyses showed that patients undergoing annulus-preserving repair had significantly higher freedom from pulmonary valve replacement than those who received TAP [22]. Although valve preservation occasionally resulted in a modest residual RVOT gradient, it substantially reduced risk of pulmonary regurgitation [20, 23], which was generally well tolerated and could be managed conservatively [24]. When TAP remains unavoidable, monocusp reconstruction has been applied to limit early PR. Meta-analytic data demonstrate similar early and late mortality rates (2.91% and 0.29% per year, respectively) and comparable reintervention rates (1.82% per year) to standard TAP repair [15]. Some studies report a transient reduction in PR risk immediately postoperatively. Still, mostconfirm that significant regurgitation develops over time [25, 26]. Although monocusp reconstruction can be performed safely with minimal additional bypass time, its long-term hemodynamic benefit remains uncertain [26–28]. Overall, contemporary evidence supports an individualized, anatomy-guided approach that favors pulmonary valve preservation whenever feasible, balancing adequate RVOT relief with long-term preservation of right ventricular function and minimizing the need for future interventions in adults with repaired TOF [15]. These comparisons largely derive from retrospective, single- or multicenter cohorts spanning different surgical eras rather than randomized trials, and selection bias favoring valve-sparing techniques in anatomically favorable patients cannot be excluded. Left ventricular systolic dysfunction is also increasingly recognized as an important prognostic factor in adults with repaired Tetralogy of Fallot. In a meta-analysis including 2,854 patients with a mean age of 28 ± 4 years and 5.6 ± 3.4 years of follow-up, cardiac adverse events (CAE) occurred in 5.1% of patients, and both continuous and categorical reductions in left ventricular ejection fraction (LVEF) were significant predictors of CAE [29]. Specifically, every 5% decrease in LVEF was associated with a 30% increase in CAE risk, while LVEF < 40% conferred a threefold higher risk than in other patients [29]. Although most studies in TOF focus on right ventricular function, these findings highlight the prognostic relevance of LV systolic dysfunction and the need to incorporate LV assessment into risk stratification models [29]. Pulmonary valve replacement (PVR) Indications and timing of intervention Pulmonary valve replacement remains a cornerstone of long-term management in adults with repaired tetralogy of Fallot. Chronic PR leads to progressive right ventricular dilatation, systolic and diastolic dysfunction, impaired ventricular–ventricular interaction, and secondary effects on the left ventricle. Over time, irreversible myocardial remodelling develops, including fibrosis and mechanical dyssynchrony, which contribute to ventricular arrhythmias and an increased risk of sudden cardiac death. Therefore, determining the optimal timing for intervention is critical and remains one of the major challenges in adult congenital heart disease (ACHD) care [30]. According to the 2020 ESC guidelines, the decision for PVR should be based on a comprehensive, individualized assessment integrating clinical symptoms, exercise capacity, serial imaging data, and functional parameters rather than isolated static cut-offs. Indications for PVR include symptomatic severe PR or at least moderate right ventricular outflow tract obstruction (Class I, Level C) [2]. In those with a native right ventricular outflow tract, a transcatheter approach is preferred whenever the anatomy allows it (Class I, Level C) [2]. In asymptomatic patients, the decision to intervene should be based on a combination of serial findings (Class IIa, Level C): progressive RV enlargement (RV end-systolic volume index [RVESVi] ≥ 80 mL/m2 or RV end-diastolic volume index [RVEDVi] ≥ 160 mL/m2), deterioration in exercise capacity, worsening tricuspid regurgitation to at least a moderate degree, evidence of declining RV systolic function or RVOTO with right ventricular systolic pressure reaching 80 mmHg or higher [2]. In addition, closure of a residual ventricular septal defect is recommended when it causes significant LV volume overload or when pulmonary valve surgery is planned (Class IIa, Level C) [2]. These recommendations are presented in Table 1. Table 1Indications for PVR after repaired TOF, based on the 2020 ESC Guidelines for Adult Congenital Heart Disease [2]InterventionTarget population/indicationCriteria (if applicable)ClassaLevelbPulmonary valve replacementSymptomatic patients with severe PRc and/or at least moderate RVOTOd—ICTranscatheter pulmonary valve intervention (TPVI)Patients with no native RV outflow tracte, when intervention is anatomically feasiblePreferred when anatomy allowsICPVR — should be consideredAsymptomatic patients with severe PR and/or RVOTOConsider intervention when ≥ 1 of the following is present:• Decrease in objective exercise capacity• progressive RV dilation to RVESVi ≥ 80 mL/m2 and/or RVEDVi ≥ 160 mL/m2 and/or progression of TR to at least moderate• progressive RV systolic dysfunction• RVOTO with RVSP > 80 mmHgIIaCResidual VSD closure — should be consideredPatients with residual VSDIf there is significant LV volume overload or if the patient is undergoing pulmonary valve surgeryIIaCAbbreviations: CMR cardiovascular magnetic resonance, LV left ventricle, PR pulmonary regurgitation, PVR pulmonary valve replacement, RV right ventricle, RVESVi right ventricular end systolic volume indexed, RVEDVi right ventricular end diastolic volume indexed, RVOTO right ventricular outflow tract obstruction, RVSP right ventricular systolic pressure, TOF tetralogy of Fallot, TPVI transcatheter pulmonary valve implantation, VSD ventricular septal defect.aClass of recommendation.bLevel of evidence.cRegurgitant fraction by CMR > 30–40%dPeak velocity > 3 m/s.ePatients with previous RVOT surgery using homografts, bovine jugular vein grafts, bioprostheses/conduits Indications for PVR after repaired TOF, based on the 2020 ESC Guidelines for Adult Congenital Heart Disease [2] Consider intervention when ≥ 1 of the following is present: • Decrease in objective exercise capacity • progressive RV dilation to RVESVi ≥ 80 mL/m2 and/or RVEDVi ≥ 160 mL/m2 and/or progression of TR to at least moderate • progressive RV systolic dysfunction • RVOTO with RVSP > 80 mmHg Abbreviations: CMR cardiovascular magnetic resonance, LV left ventricle, PR pulmonary regurgitation, PVR pulmonary valve replacement, RV right ventricle, RVESVi right ventricular end systolic volume indexed, RVEDVi right ventricular end diastolic volume indexed, RVOTO right ventricular outflow tract obstruction, RVSP right ventricular systolic pressure, TOF tetralogy of Fallot, TPVI transcatheter pulmonary valve implantation, VSD ventricular septal defect. aClass of recommendation. bLevel of evidence. cRegurgitant fraction by CMR > 30–40% dPeak velocity > 3 m/s. ePatients with previous RVOT surgery using homografts, bovine jugular vein grafts, bioprostheses/conduits The recently published Guidelines of the Society of Thoracic Surgeons/World Society for Pediatric and Congenital Heart Surgery/European Congenital Heart Surgeons Association formulate recommendations for implementing PVR slightly differently. In both symptomatic and asymptomatic patients, the starting point for considering PVR eligibility is moderate or greater regurgitation. In symptomatic patients with rToF PVR is recommended to improve symptoms attributable to moderate or greater pulmonary regurgitation (regurgitant fraction ≥ 25%) (Class I, Level B). In asymptomatic rToF patients, additional criteria are needed to qualify for PVR—2 or more of the following based on cardiac magnetic resonance: RVEDV ≥ 160 mL/m2, RVESV ≥ 80 mL/m2, RVEF < 0.47, LVEF < 0.55 (Class IIa, Level B). PVR may be considered in asymptomatic rToF patients with moderate or greater pulmonary insufficiency and RVESV ≥ 80 mL/m2 alone (Class IIb, Level B) [10]. Advanced cardiac imaging plays a central role in patient evaluation. Cardiac magnetic resonance is the gold standard for quantifying RV size, function, and myocardial fibrosis [30, 31]. Parameters such as RV ejection fraction < 42% and RV mass > 39 g/m2 have been independently associated with increased risk of adverse events and mortality [32, 33]. Furthermore, speckle-tracking echocardiography enables detection of subclinical RV dysfunction and mechanical dyssynchrony before overt failure [34]. Cardiopulmonary exercise testing metrics—including peak VO₂, VE/VCO₂ slope, and heart rate reserve—along with biomarkers such as brain natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP), provide complementary prognostic information regarding hemodynamic burden and risk stratification [30, 35]. Nonetheless, these thresholds were derived largely from observational cohorts and expert consensus rather than from randomized comparisons of early versus deferred intervention, and their applicability across evolving surgical eras and repair techniques remains uncertain. Clinical outcomes after pulmonary valve replacement The most recent meta-analysis including 84 studies and 7544 patients showed that pulmonary valve replacement is associated with low mortality rates—0.87% at 30 days, 2.7% at 5 years, and 6.2% at 10 years [36]. The pooled rates of redo PVR were 3.7% and 16.8% at 5 and 10 years, respectively [36]. Pulmonary valve replacement significantly reduced indexed RV end-diastolic and end-systolic volumes, accompanied by improved RV ejection fraction, indicating reverse remodelling and relief of volume overload. Left ventricular ejection fraction also improved, despite an increase in LV end-diastolic volume, reflecting a favorable effect on biventricular interaction [36]. Plasma brain natriuretic peptide (BNP) levels decreased significantly, supporting hemodynamic improvement after PVR [36]. However, the degree of RV functional recovery after PVR varies [37–39]. patients generally experience symptomatic improvement and better New York Heart Association (NYHA) functional class [37]. However, the impact of PVR on exercise capacity, QRS duration, and ventricular arrhythmia burden remains inconsistent across studies, with some reporting improvements in these parameters following valve replacement [40, 41]. In contrast, others show minimal or no significant change [39, 42]. These discrepancies likely reflect the influence of preoperative ventricular geometry and function, the timing of intervention, and other patient-specific factors on postoperative outcomes [43, 44]. Meta-regression analysis showed that larger preoperative RV end-diastolic and end-systolic volumes were associated with a lower likelihood of RV volume normalization after surgery, suggesting that delayed intervention may limit the potential for full recovery of ventricular function [36]. These findings emphasize the importance of optimal timing for PVR and the need for reliable predictors of postoperative remodeling in adults with repaired TOF. Surgical vs transcatheter pulmonary valve replacement PVR can be performed surgically (SPVR) or percutaneously (TPVR). Surgical pulmonary valve replacement is performed under general anesthesia utilizing extracorporeal circulation (ECC). Access to the heart can be obtained through median sternotomy or left thoracotomy. The most common access is the sternotomy, giving a good view of the heart and great vessels, but surgeons usually have to deal with pericardial adhesions after previous operations. After cannulating the right atrium (or the superior and inferior vena cava) and the ascending aorta, cardiopulmonary bypass is initiated. In most cases, the pulmonary valve is replaced on the beating heart; however, if there is a residual intracardiac shunt that needs to be fixed or there is insufficient blood drainage making the operation uncomfortable, the aorta is clamped, and the heart is stopped using cardioplegic solution. After dissecting the pulmonary trunk and right ventricular outflow tract (RVOT), the valve is sutured in the RVOT. Another access to the heart for PVR is through the left anterolateral thoracotomy. In this case, ECC is performed by cannulating the femoral vein and artery. After opening of the 4th intercostal space, the heart is exposed. In most cases, access to the pulmonary trunk is fine, and pulmonary valve replacement can be performed safely with the heart beating, but in this case, repair of any additional heart lesions is impossible. Transcatheter pulmonary valve replacement is a minimally invasive procedure performed in catheterization laboratory under general anesthesia. Access to the heart is usually obtained via the femoral vein or, occasionally, via the internal jugular vein. The valve fixed on a catheter can be introduced directly into the RVOT and pulmonary trunk or can be placed inside a stent which is deployed in RVOT before valve introduction, giving the „landing zone” for the valve. When the position of the prosthesis is settled the balloon is inflated and the valve is stabilized. Table 2 summarises the currently available transcatheter pulmonary valve systems. Surgical PVR is a well-established procedure with low perioperative mortality (0–4%) and excellent hemodynamic outcomes [36, 45, 46]. It allows implantation of various types of biological prostheses or conduits, with freedom from reintervention reported at approximately 99% at 1 year, 94–98% at 5 years, 83–96% at 10 years, and 52–89% at 15 years, with outcomes influenced by factors such as patient age at the time of implantation and the size of the valve [30, 36]. Transcatheter PVR has emerged as a minimally invasive alternative. Early-generation systems enabled effective valve implantation in patients with a prior conduit or bioprosthesis [47, 48], while newer systems have expanded indications to patients with a dilated, non-conduit RVOT [47, 49, 50]. Direct head-to-head comparisons are limited because of differing patient populations and indications [50, 51]. Still, both techniques show low periprocedural mortality, generally ranging from 0.5% to 2% [51, 52]. SPVR requires sternotomy or thoracotomy, resulting in longer recovery times [51, 53], whereas TPVR is minimally invasive and avoids open-heart surgery. Complications differ between modalities, with SPVR carrying risks such as sternal wound infections and TPVR being associated with valve embolization [52], but overall rates of repeat interventions appear comparable [53–55]. Hospitalization is generally longer after SPVR [51, 53], although overall short [51, 56] and long-term [57] costs are similar. Choice between SPVR and TPVR should be individualized, considering patient age, body size, RVOT anatomy, prior valve or conduit implantation, comorbidities, number of previous sternotomies, and expected need for future interventions [58, 59]. SPVR is typically indicated for patients with complex anatomy, the need for concomitant cardiac surgery, or when transcatheter implantation is not feasible. In contrast, TPVR is preferred in high surgical-risk patients, those with prior conduits or bioprostheses, and increasingly in patients with a native or patched RVOT as newer transcatheter technologies expand eligibility [30]. A multidisciplinary approach involving cardiologists, surgeons, and interventionalists is essential to optimize both short- and long-term outcomes, with careful lifetime planning for repeated interventions. Emerging transcatheter technologies may further expand the applicability of minimally invasive approaches in selected patients, offering an effective and safe alternative to traditional surgical replacement [30]. Head-to-head comparative data between surgical and transcatheter approaches remain limited, and much of the evidence guiding modality selection comes from heterogeneous, non-randomized cohorts with differing baseline anatomy and follow-up duration. Table 2Characteristics of currently available transcatheter pulmonary valves. Modified by the authors based on Patel ND, Levi DS, Cheatham JP, Qureshi SA, Shahanavaz S, Zahn EM. Transcatheter pulmonary valve replacement: a review of current valve technologies. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100,452. Published 2022 Sep 16. https://doi.org/10.1016/j.jscai.2022.100452ValveMelodySapien 3HarmonyAlterra Adaptive PrestentPulstaVenus P-ValveMed-Zenith PT-ValveImplantation typeBalloon-expandableBalloon-expandableSelf-expandingSelf-expandingSelf-expandingSelf-expandingSelf-expandingTarget anatomyConduit, bioprosthetic valveConduit, bioprosthetic valveNative RVOTNative RVOTNative RVOTNative RVOTNative RVOTLeaflet materialBovine jugular veinBovine pericardiumPorcine pericardiumN/APorcine pericardiumPorcine pericardiumPorcine pericardiumStent frame (material)Platinum-IridiumCobalt-ChromiumNitinolNitinolNitinolNitinolNitinolValve size at implant [mm]18/20/2220/23/26/2922/25Accommodates 29 mm Sapien 318/20/22/24/26/28/30/3228/30/32/34/3620/23/26Frame length post-deployment [mm]26/24/2115.5/18/20/22.555/514928/38, 31/38, 33/38, 3825/30 (does not include flared ends)38–54Sheath size (French)2214, 16251618, 2022, 2421Abbreviations: RVOT right ventricular outflow tract, N/A not applicable Characteristics of currently available transcatheter pulmonary valves. Modified by the authors based on Patel ND, Levi DS, Cheatham JP, Qureshi SA, Shahanavaz S, Zahn EM. Transcatheter pulmonary valve replacement: a review of current valve technologies. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100,452. Published 2022 Sep 16. https://doi.org/10.1016/j.jscai.2022.100452 Abbreviations: RVOT right ventricular outflow tract, N/A not applicable Repeat PVR and long-term follow-up Repeat pulmonary valve replacement is indicated in patients with dysfunction of a previously implanted bioprosthetic valve, which may present as stenosis, regurgitation, or mixed disease. Transcatheter PVR can be performed within a previously implanted surgical bioprosthesis or as a valve-in-valve procedure. TPVR is generally preferred in patients at higher surgical risk or when a less invasive approach is desirable. Current guidelines and suggested criteria for repeat PVR focus on pulmonary regurgitation, right ventricular volume overload, RVOT obstruction, and declining ventricular function, emphasizing a multidisciplinary approach to optimize lifetime management and timing of intervention [30]. Recent advances have integrated clinical (age, obesity, type of primary repair) and imaging parameters (RV end-systolic volume index, biventricular global function index) to improve timing and patient selection for PVR [60]. A proposed threshold of INDICATOR risk score ≥ 3 is suggested to guide consideration of PVR, aiming to intervene before irreversible myocardial damage occurs [30]. Despite significant hemodynamic improvement after PVR, residual myocardial fibrosis and conduction abnormalities often persist, meaning arrhythmic risk remains. Electrophysiological assessment may identify inducible ventricular tachycardia and guide substrate-directed ablation strategies before or during pulmonary valve replacement [30, 61]. In this context, systematic electrophysiological evaluation before transcatheter pulmonary valve replacement deserves particular attention. Although routine invasive electrophysiological study (EPS) is not currently recommended for all patients undergoing TPVR, recent American scientific statements emphasize that transcatheter valve implantation may limit access to critical ventricular tachycardia substrates within the right ventricular outflow tract.Consequently, identifying slow-conducting anatomical isthmuses and performing catheter ablation before valve implantation may offer a unique opportunity to reduce future arrhythmic risk in selected patients with repaired tetralogy of Fallot. This concept is particularly relevant in patients with extensive RV scarring, QRS fragmentation, ventricular dysfunction, documented ventricular arrhythmias, or other markers of increased sudden cardiac death risk [30, 62]. Future studies are needed to determine whether routine clinical practice should incorporate a more systematic pre-TPVR electrophysiological strategy. Long-term management after PVR requires lifelong, multidisciplinary follow-up in specialized ACHD centres, including periodic clinical evaluation, ECG, Holter monitoring, CPET, and serial CMR every 12–36 months depending on disease stage [30, 31]. Surveillance aims to detect progressive RV dysfunction, prosthetic degeneration, or arrhythmia burden. Future directions include improving prosthesis durability and biocompatibility, reducing infection risk, and developing regenerative or pharmacologic approaches to reverse RV remodeling [30]. Appropriately timed and individualized PVR—supported by advanced imaging, functional assessment, and comprehensive risk stratification—remains fundamental to optimizing outcomes in adults with repaired tetralogy of Fallot. Endocarditis risk Infective endocarditis (IE) is a well-recognized complication after pulmonary valve replacement in repaired tetralogy of Fallot, with risk varying by valve type and implantation approach. A meta-analysis of 15 comparison groups (4,706 patients) found significantly higher IE risk with transcatheter pulmonary valve replacement (TPVR) than with surgical replacement (SPVR) (OR 2.68, 95% CI: 1.83–3.93) [63]. Among transcatheter valves, earlier pooled data showed markedly higher IE incidence with Melody than Sapien (4.9% vs. 1.3%) [64], though the largest multicenter cohort to date (2,476 patients) found this difference lost significance after adjustment for confounders such as younger age, prior IE, and residual RVOT gradient [65]; a 2023 meta-analysis again favored Sapien [66], so valve-specific risk remains debated. Newer self-expanding platforms show promising but less mature data: pooled Harmony follow-up (3–5 years) reports IE in ~ 2–3% of patients [67], the Pulsta valve’s CE Approval Study recorded only one IE case among 57 patients over a 4.1-year median follow-up [68], and Venus P-valve data remain limited to single-center series with infrequently reported IE, though stent-frame complications are more commonly emphasized [69]—all with smaller cohorts and shorter follow-up than Melody or Sapien. Overall, TPVR appears to carry higher IE risk than SPVR, and rigorous antibiotic prophylaxis and vigilant surveillance remain essential across all PVR modalities, regardless of valve type or approach. Antiplatelet therapy after pulmonary valve replacement Both surgical and transcatheter bioprosthetic pulmonary valves remain thrombogenic until endothelialization is complete, typically within three months of implantation; low-dose aspirin is therefore commonly used to reduce valve thrombosis and thromboembolic risk during this period [70, 71]. However, no formal guideline governs antithrombotic management after TPVR, and manufacturer instructions for use for currently available devices (Melody, SAPIEN 3/Alterra, Harmony, Pulsta) specify no standardized agent, dose, or duration, stating only that intolerance of antiplatelet or anticoagulant therapy is a contraindication to the procedure. In the absence of device-specific guidance, expert consensus statements provide pragmatic direction: a 2024 Asian TPVR consensus recommends single antiplatelet therapy for 6 months after TPVR in patients without another indication for anticoagulation [72], while Thrombosis Canada suggests aspirin 81 mg daily or warfarin (INR target 2.5) for 3 months after bioprosthetic pulmonary valve replacement [73]. Practice is correspondingly heterogeneous: in a survey of 109 interventional cardiologists, 76.5% used aspirin monotherapy after TPVR, most did not counsel patients on avoiding enteric-coated formulations, proton-pump inhibitors, or NSAIDs, and prescribed doses varied widely, with 56% using a fixed 70–100 mg dose, 28% dosing by weight, and 7.5% using a fixed 325 mg dose [71]. Based on this heterogeneity and a review of the literature, the survey authors proposed an empirical regimen pending formal guidelines: aspirin 5 mg/kg (up to 50 kg) or 325 mg (above 50 kg), using non-enteric-coated preparations only, with avoidance of concomitant NSAIDs and PPIs and structured counseling on adherence [71]. Clinical consequences of this variability are increasingly recognized. In a Pulsta valve series, subclinical leaflet thrombosis, termed hypo-attenuated leaflet thickening (HALT), on cardiac CT was more common after short-term antiplatelet therapy and in patients with larger valve sizes, supporting routine imaging surveillance and individualized, potentially lifelong, aspirin use [74]. Separately, abrupt aspirin discontinuation—often around unrelated invasive procedures—was identified as an independent predictor of Melody valve infective endocarditis [75]. For surgical bioprosthetic PVR, however, a retrospective series found no difference in 10-year freedom from reintervention between aspirin use for ≤ 12 months versus longer, suggesting limited added benefit beyond the endothelialization period for surgical valves [70]. In the absence of randomized data, most centers empirically continue low-dose aspirin for at least three months after TPVR, often lifelong; dedicated prospective studies and consensus guidelines are needed to standardize the antiplatelet agent, dose, and duration after both surgical and transcatheter pulmonary valve replacement. Arrhythmias Arrhythmias remain among the most significant late complications in adults after surgical repair of tetralogy of Fallot, representing a major cause of morbidity and sudden cardiac death (SCD) despite advances in surgical and medical management [62]. Both atrial and ventricular arrhythmias are common and arise primarily from macroreentrant circuits formed by the interaction of congenital anatomy, surgical scars, and ventricular remodeling. Monomorphic ventricular tachycardia (VT) is the principal arrhythmic mechanism underlying SCD in this population, typically involving slowly conducting anatomical isthmuses bordered by non-excitable structures such as ventriculotomy scars, valve annuli, and VSD patches. The conduction velocity through these isthmuses (< 0.5 m/s) correlates strongly with VT inducibility in over 90% of cases [76, 77]. The meta-analysis by Possner et al. identified multiple independent risk factors for ventricular arrhythmia and mortality in rTOF. Risk increased with patient age (3.9% per year), older age at repair (3.4% per year), prior palliative shunts (OR ≈ 3.1), additional thoracotomies (OR ≈ 1.4 per procedure), ventriculotomy (OR ≈ 2.3), and biventricular dysfunction—particularly moderate or severe right ventricular impairment (OR ≈ 2.2). Each 1% reduction in LVEF increased VT or death risk by 4.9%, while higher RV end-diastolic volume and QRS prolongation also correlated with adverse outcomes. Each millisecond increases in QRS duration raised VT risk by 3.1%, though the conventional 180 ms threshold was not independently predictive [78]. Fragmented QRS emerged as a more sensitive marker, reflecting myocardial fibrosis and providing superior prognostic discrimination [62, 78]. Importantly, Possner’s analysis did not confirm independent associations for pulmonary or tricuspid regurgitation severity or prior pulmonary valve replacement, emphasizing that arrhythmic risk depends more on surgical scarring and ventricular function than on valvular status. In adults with repaired tetralogy of Fallot, the prevalence of atrial tachyarrhythmias increases with age. In a multicenter cohort, 43% of patients developed sustained arrhythmias or required arrhythmia-related interventions, and atrial arrhythmias accounted for approximately 20% of these cases [62]. The most frequent types are intra-atrial reentrant tachycardia and cavotricuspid isthmus–dependent atrial flutter, while the incidence of atrial fibrillation (AF) rises significantly after the fourth decade of life [79, 80]. Right atrial dilation and at least moderate tricuspid regurgitation are major risk factors for atrial arrhytmias [79]. The presence of AF in TOF patients is associated with reduced survival and a fourfold increase in heart failure–related hospitalizations [79, 81]. Bradyarrhythmias are less common but clinically relevant, usually resulting from surgical injury or atrial scarring affecting the sinus or atrioventricular (AV) node. About 7–9% of patients eventually require pacemaker implantation, most often for sinus node dysfunction or high-grade AV block [82]. Risk factors include progressive PR prolongation, bifascicular block, and delayed recovery of postoperative AV block, which increases long-term sudden death risk sixfold [83]. Ventricular arrhythmias and SCD remain key determinants of long-term outcomes, with reported late mortality ranging from 10–22% over 30 years [84, 85] and annual SCD incidence of 0.9–3% [86, 87]. Risk is markedly higher in patients with complex anatomy (e.g., pulmonary atresia, double outlet right ventricle) or extensive right ventricular scarring [88]. Several multicenter studies have developed advanced risk models for SCD prediction in adults with rTOF. The Spanish ACHD score (360 patients) demonstrated excellent predictive accuracy (C-statistic = 0.91) [88], while the PREVENTION-ACHD score identified ischemic heart disease as a novel independent risk factor increasing SCD risk four- to eightfold [88, 89]. A prospective MRI-based model including 550 rTOF patients demonstrated that right ventricular late gadolinium enhancement (RV LGE) is the strongest independent predictor of mortality [90]. Patients classified as high risk had an annual mortality of 4.4% versus < 0.2% in the lowest-risk group and a 10-year mortality of 36% vs 1%. Once the extent of LGE was included, traditional parameters such as QRS duration, surgical history, or nonsustained VT lost independent predictive value, indicating myocardial fibrosis as the major arrhythmogenic substrate [90]. Another machine-learning model (AiTOR), derived from electronic records and incorporating 57 clinical and imaging variables, achieved predictive performance comparable to other modern scores. Although effective in identifying adverse outcomes such as heart failure or sustained VT, the number of SCD events was low (< 3%), limiting its validation for sudden death. Even with model sensitivity approaching 95%, residual SCD risk persists (≈0.2% annually). Individualized risk stratification integrating CMR findings, functional testing, and continuous rhythm monitoring remains essential, as conventional guidelines may over- or underestimate true risk in this heterogeneous population. Catheter ablation targeting the four characteristic right ventricular isthmuses (between the tricuspid or pulmonary annuli, VSD patch, and ventriculotomy scar) achieves acute success in 70–80% of cases and reduces VT recurrence, Implantable cardioverter-defibrillators shocks, and mortality [91]. However, efficacy may be limited by prosthetic material or deep scar tissue. Although antiarrhythmic drugs alone provide limited benefit, combination therapy with agents such as amiodarone or sotalol can enhance ablation outcomes [91]. Beta-blockers may benefit patients with polymorphic VT not amenable to ablation, and class III agents can be considered when beta-blockade is insufficient [62]. Implantable cardioverter-defibrillators remain the cornerstone for secondary prevention after sustained VT or cardiac arrest and may be used for primary prevention in patients with multiple high-risk features [62, 91]. However, ICD complications occur in up to 40% of patients at 7 years [92], including inappropriate shocks (≈25%), lead failure, and infections [82, 93]. Subcutaneous ICD may reduce these risks but are unsuitable for up to 40% of rTOF patients due to T-wave oversensing related to wide QRS complexes and right bundle branch block morphology [94, 95]. Electromechanical dyssynchrony and right bundle branch physiology impairs coordinated RV contraction [96]. Studies on cardiac resynchronization therapy in congenital heart disease have shown improvements in RV contraction mechanics during both acute and chronic phases [97, 98] and can be recommended for RV dysfunction with LVEF ≤ 35% or > 40% ventricular pacing burden [99]. Nevertheless, areas of scar tissue and patch material in the RV outflow tract and ventricular septal defect repair remain akinetic, limiting energy transfer and overall efficiency. Surgical removal of dysfunctional RVOT tissue at the time of pulmonary valve replacement does not appear to offer additional benefit compared with isolated valve replacement [39]. Emerging tissue engineering approaches may help address these limitations, for example through biological patches seeded with cardiomyocytes or endothelial cells to restore contractile or vascular function [100]. Further innovations, such as the implantation of contractile bands, could potentially enhance RV biomechanics and improve overall ventricular performance [101]. Overall, the pathophysiology and management of arrhythmias in repaired TOF are multifactorial, involving structural, surgical, and electrophysiological determinants. Early repair, preservation of biventricular function, detailed scar assessment using cardiac MRI, and individualized strategies combining ablation, device therapy, and pharmacologic management are essential to mitigate arrhythmic burden and improve survival in this population. Aortopathy Aortopathy is a recognized late complication in adults with repaired Tetralogy of Fallot, resulting from intrinsic aortic wall abnormalities combined with long-standing hemodynamic alterations. Histopathological studies. At the same time, chronic preoperative volume overload and increased systemic-to-pulmonary flow contribute to progressive dilation of the aortic root, showing moderate cystic medial necrosis of the ascending aorta, suggesting an inherent aortopathy component in TOF. In contrast, chronic preoperative volume overload and increased systemic-to-pulmonary flow contribute to progressive aortic root dilation [102, 103]. Aortic root dilation is highly prevalent after TOF repair, with one pediatric cohort reporting z-score–defined dilation (z > 2) in 88% of patients at the aortic annulus, 87% at the sinus of Valsalva (SV), 61% at the sinotubular junction (STJ), and 63% at the ascending aorta [104]. In adult cohorts, Ichikawa et al. reported aortic root dilation in 37% (58/156) of TOF patients, most frequently affecting both the SV and STJ, with only a few cases exceeding 50 mm in diameter [105]. Despite compensatory changes, reduced coaptation length and dilation of the annulus, SV, and STJ were associated with moderate or severe AR, observed in 7 patients, all with El Khoury type 1a or 1b dysfunction patterns [105]. Even mild to moderate AR correlated with in left ventricular ejection fraction (LVEF), highlighting the need for close echocardiographic surveillance [5]. Risk factors for progressive aortic dilation include severe preoperative cyanosis, right ventricular outflow tract obstruction, older age at repair, larger left ventricular end-diastolic diameter, male sex, right aortic arch [106], and 22q11 deletion syndrome [107, 108]. Despite the high prevalence of aortic dilation, aortic aneurysm and dissection are rare in this population. A large population-based study from Texas, spanning 13.5 years, showed that aortic dissection in TOF patients was exceptionally uncommon, with many cases occurring during the same hospitalization as corrective surgery, suggesting an iatrogenic origin [109]. All reported cases of dissection involved patients with markedly enlarged aortic roots exceeding 55 mm in diameter, with individual case reports describing roots of 6.1 cm and 6.45 cm [110, 111]. Current guidelines recommend surgical intervention when the ascending aortic diameter reaches ≥ 55 mm, or earlier in cases with > 5–10 mm annual growth, moderate or greater AR, or a family history of dissection. When the ascending aorta measures 50–55 mm, management should be individualized based on comorbidities, associated lesions, and life expectancy. In these cases, reduction ascending aortoplasty may be sufficient, while aortic root replacement with coronary reimplantation is indicated for severe root dilation or effacement of the sinotubular junction. If the ascending aorta measures ≥ 55 mm with preserved sinotubular junction and sinuses ≤ 40 mm, a supracoronary tube graft may be considered [112–114]. These surgical thresholds are largely extrapolated from guidelines developed for Marfan syndrome, bicuspid aortic valve disease, and the general population, as TOF-specific outcome data directly linking a given aortic diameter to dissection risk remain scarce. No clear consensus exists on pharmacologic strategies to prevent progression of aortic dilation [115, 116]. A prospective analysis by Woudstra et al., drawn from a randomized, placebo-controlled cohort of adults with repaired TOF (the REDEFINE trial), examined the effect of losartan therapy on aortic root growth over two years and found progression to be generally slow and statistically non-significant, with no reduction in growth rate compared with placebo; these findings do not support more aggressive pharmacologic or prophylactic surgical strategies for aortic root dilation in this population, as observed growth rates resembled those of the general population [117]. Valve-sparing root replacement (VSRR), including David (reimplantation) and Yacoub (remodeling) procedures, is increasingly favored over composite valve grafts as it preserves the native aortic valve, maintains physiologic hemodynamics, and avoids lifelong anticoagulation. In extensive meta-analyses, the perioperative mortality associated with VSRR was reported to be between 1 and 2%, increasing to approximately 7% for emergency cases such as acute aortic dissection and 4.6% for reoperations [118]. The most frequent postoperative complication was surgical bleeding necessitating thoracic reintervention, occurring in about 5% of cases. In the long-term follow-up study by David et al. involving 333 patients (mean age 46 years), 15-year outcomes demonstrated excellent durability, with 78% overall survival, 97% freedom from reoperation, 96% freedom from moderate or severe aortic regurgitation, and 93% freedom from thromboembolic events. Notably, these results were achieved after excluding patients with advanced valvular degeneration [119]. Postoperative outcomes are strongly dependent on surgical expertise, and long-term follow-up remains essential to detect recurrence of dilation or valvular dysfunction [120]. These outcomes represent the general population of patients undergoing VSRR, not exclusively those with repaired Tetralogy of Fallot. Several reports describe performing the David procedure after TOF repair [121, 122], typically in relatively young patients aged 30–50 years at the time of surgery. In these cases, none of the patients had severe aortic regurgitation, and the ascending aorta did not exceed 55 mm in diameter. Overall, aortopathy in repaired TOF represents a multifactorial, progressive process requiring lifelong monitoring and individualized timing of intervention. Pharmacological management of right ventricular dysfunction RAAS inhibition Pharmacological management of adults following surgical correction of tetralogy of Fallot remains a major challenge, particularly in the context of right ventricular dysfunction. Despite well-documented activation of the renin–angiotensin–aldosterone system (RAAS) in settings of RV pressure overload, clinical trials have not demonstrated significant benefit from RAAS inhibition in improving RV function or patient outcomes in this population [117, 123–125]. The randomized, double-blind REDEFINE trial by Bokma et al. evaluated the impact of losartan (150 mg/day) versus placebo in adults with repaired TOF and reduced RV ejection fraction (< 50%). Over 18–24 months of treatment, there was no significant difference in the change of RV ejection fraction measured by cardiac MRI between groups. Secondary endpoints, including left ventricular function, exercise capacity, NT-proBNP levels, and quality of life, were similarly unaffected. Pre-specified subgroups—including patients with symptoms, restrictive RV physiology, previous pulmonary valve replacement, severely reduced RVEF, or QRS fragmentation—showed no benefit. An exploratory post hoc analysis did suggest a modest improvement in RVEF in a small subgroup with nonrestrictive RV and incomplete remodeling, but this finding requires further confirmation due to the small sample size involved. Thus, there is currently no rationale for routine use of losartan or other RAAS inhibitors in asymptomatic adult TOF patients with mild RV dysfunction, and any potential benefit appears limited to narrowly defined subpopulations for whom large-scale trials are still needed [123]. Animal studies support the limited efficacy of RAAS inhibitors. Akazawa et al. showed that although losartan administration in a rat model of severe pulmonary regurgitation significantly reduced RV fibrosis, this did not translate into improvements in RV function, chamber size, or diastolic indices. These results further suggest that while RAAS blockade may ameliorate some aspects of adverse RV remodeling, it does not improve chamber function in chronic volume overload post-TOF repair and cannot be recommended as an effective therapy for RV dysfunction in this context. [125]. Alternative RAAS-based therapies Interestingly, some positive findings have been reported with other RAAS inhibitors, but these benefits have been observed primarily in parameters related to left ventricular function rather than right ventricular dysfunction. Some studies [126, 127]. found that six months of ramipril (10 mg/day) led to stabilization or improvement in left ventricular (LV) systolic and diastolic function, particularly in TOF patients with chronic pulmonary regurgitation and restrictive RV physiology. Improvements included increased LV long-axis shortening, higher peak systolic and early diastolic velocities, and transmitral E/E’. In the subgroup of patients with restrictive right ventricular physiology, ramipril produced marked improvements in peak late diastolic velocity (A), and the transmitral early to late diastolic velocity ratio (E/A). No significant differences in blood pressure changes were observed between groups, and LV mass did not change significantly, but systolic function was preserved or improved in those treated with ramipril.​​ Nevertheless, further studies involving comprehensive biventricular assessment are warranted to determine the broader clinical impact of RAAS inhibitors in this population [127]. The novel combination of valsartan and sacubitril appears promising, with a small cohort showing improved echocardiographic parameters and reduced NT-pro-BNP levels over six months [128, 129]. However, available evidence remains limited and insufficient to support routine clinical use in this population. Emerging pharmacological therapies Recent therapeutic strategies have also explored agents outside the RAAS pathway. Experimental studies in rats suggest that SGLT2 inhibitors may lower pulmonary pressures [130, 131], but no improvement in right ventricular function or remodeling has been observed [132], and clinical data on primary RV dysfunction are limited to isolated case reports [133]. Phosphodiesterase-5 (PDE5) inhibitors have recently been found to enhance right ventricular contraction potentially [134, 135]. In experimental models of RV pressure overload, PDE5 expression is increased in remodeled RV myocardium, and its inhibition produces multiple effects beyond afterload reduction [136]. In rats with pulmonary artery banding, sildenafil improved RV diastolic function and limited ventricular dilation [137]. These diastolic benefits may be linked to increased titin phosphorylation, making the myocardium more compliant [138], although the role of titin in RV diastolic dysfunction in patients with repaired tetralogy of Fallot remains unproven [124]. Emerging developments: advanced imaging, artificial intelligence, and novel technologies Advanced imaging, artificial intelligence, and computational modeling These tools aim to shift decision-making from population-based thresholds toward individualized, data-driven prediction [139, 140]. While CMR remains the reference standard for biventricular assessment, deep-learning algorithms (e.g., U-Net–based CNNs) now enable automated segmentation and 3D biventricular shape modeling with reproducibility comparable to manual analysis [139, 140]. 4D flow CMR adds detailed, retrospective quantification of intracardiac flow and kinetic energy beyond conventional 2D phase-contrast imaging [141]. In contrast, native T1 mapping and extracellular volume quantification enable non-invasive assessment of diffuse RV fibrosis, a substrate increasingly linked to adverse outcomes [142]. Feature-tracking strain has identified RV long-axis strain and right atrial area as independent predictors of outcome [143], and patient-specific computational models extend phenotyping beyond ejection fraction to intracardiac flow and arrhythmia risk [144, 145]. AI applied to the ECG—a widely available, inexpensive signal—can estimate probability of adverse ventricular remodeling and predict 5-year mortality, with saliency mapping identifying QRS fragmentation, low-amplitude QRS, and flattened T waves as high-risk features [146, 147]. Such tools may triage patients toward earlier CMR and flag candidates for pulmonary valve replacement who might otherwise be missed [148]; a recently developed, multicenter-validated AI-ECG biomarker has similarly been proposed to reduce reliance on serial CMR [149], though prospective validation is still needed. Whereas existing multiparametric risk scores (AiTOR, the lesion-specific MRI-based model, the Spanish ACHD calculator, and the INDICATOR score) support population-level stratification, newer machine-learning approaches aim to integrate clinical, imaging, hemodynamic, and wearable-derived data into composite, individualized, continuously updated risk models [88, 90, 91], with some already showing improved discrimination for major adverse cardiovascular events over conventional markers [150]. However, most remain single-center and lack external validation or integration into guidelines. Transcatheter and regenerative technologies Transcatheter therapy is expanding beyond balloon-expandable valves: self-expanding nitinol valves (e.g., Harmony TPV) now accommodate large, native RV outflow tracts, with sizing guided by gated CT angiography [67, 151] and ongoing surveillance for durability and device-specific endocarditis [152]. The field is also moving toward biodegradable, tissue-engineered platforms, where a resorbable scaffold is progressively replaced by the patient’s own, potentially growth-capable tissue—an approach that could overcome conventional bioprostheses’ inability to grow with the patient and reduce calcification. Proof-of-concept large-animal studies show encouraging midterm performance [153–155], though long-term analyses reveal heterogeneous tissue regeneration and a persistent risk of mismatch between scaffold degradation and neotissue formation [156]. Together, these advances promise earlier detection of ventricular deterioration and more precise reintervention timing. However, translating these advances into guideline-integrated practice will require multicenter validation and prospective evaluation of patient-centered outcomes. Conclusion Repaired tetralogy of Fallot is no longer a cured defect but a chronic, lifelong condition marked by progressive right ventricular dysfunction, arrhythmic risk, and aortopathy. Multimodality imaging remains essential for early detection, pulmonary valve replacement the cornerstone intervention for volume overload, and individualized, threshold-based decision-making the standard for both PVR and aortic surgery timing. Conventional pharmacological therapies have not shown disease-modifying benefit for right ventricular dysfunction, leaving surveillance and timely reintervention as the main levers for improving outcomes. Emerging tools—AI-based risk prediction, advanced imaging biomarkers, and novel transcatheter technologies—are promising but still require prospective validation. Until then, lifelong follow-up in specialized adult congenital heart disease centers remains essential to optimizing long-term prognosis. Author contributions Conceptualization, K.C., M.M., A.B.-D. and M.B.; methodology, K.C., M.M. and A.C.; formal analysis, K.C., M.M. and K.K.; writing—original draft preparation, K.C. and M.M.; writing—review and editing, K.C., M.M., A.C., K.K., M.B. and A.B.-D.; visualization, A.C. and K.C.; supervision, A.B.-D., M.M. and M.B.; funding acquisition, A.B.-D. All authors have read and agreed to the published version of the manuscript. K.C. – Krzysztof Cienkowski M.M. – Dr Maciej Moll A.C. – Alicja Cienkowska K.K. – Dr Karolina Kupczynska M.B. – Prof. dr hab. n. med. Maciej Banach A.B.-D. – Prof. dr hab. n. med. Agata Bielecka-Dąbrowa. Funding The APC was funded from the statutory funds of the Polish Mother’s Memorial Hospital Research Institute in Lodz. Data availability No datasets were generated or analysed during the current study. Declarations Ethical standards The manuscript does not contain clinical studies or patient data. Competing interests The authors declare no competing interests. Footnotes Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.